Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02992132 · ClinicalTrials.gov registry record · Phase 2
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT02992132 is a Phase 2 study that was terminated before completion, run by ACADIA Pharmaceuticals. The registered enrollment target is 111 participants.
The verdict
NCT02992132, a Phase 2 study, was terminated before completion, sponsored by ACADIA Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment
Interventions
- OTHER Placebo
- DRUG Pimavanserin 34 mg
- DRUG Pimavanserin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02992132
The ClinicalTrials.gov registry entry for NCT02992132 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02992132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02992132 about?
NCT02992132 is a clinical study titled "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)". To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment
What is the current status of trial NCT02992132?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2016-11. Estimated completion is 2018-02-16.
What interventions are being tested in trial NCT02992132?
The interventions under investigation include: Placebo (OTHER), Pimavanserin 34 mg (DRUG), Pimavanserin 20 mg (DRUG).
Who is sponsoring clinical trial NCT02992132?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.